Eris Lifesciences [ERIS] vs Jubilant Pharmova [JUBLPHARMA] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Eris Lifesciences Ltd. wins in 9 metrics, Jubilant Pharmova Ltd. wins in 11 metrics, with 0 ties. Jubilant Pharmova Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Eris Lifesciences Ltd. | Jubilant Pharmova Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 44.25 | 33.71 | Jubilant Pharmova Ltd. |
| Price-to-Book Ratio | 6.15 | 2.21 | Jubilant Pharmova Ltd. |
| Debt-to-Equity Ratio | 68.19 | 43.87 | Jubilant Pharmova Ltd. |
| PEG Ratio | 2.33 | -0.74 | Eris Lifesciences Ltd. |
| EV/EBITDA | 17.91 | 13.71 | Jubilant Pharmova Ltd. |
| Profit Margin (TTM) | 14.06% | 5.46% | Eris Lifesciences Ltd. |
| Operating Margin (TTM) | 26.38% | 7.95% | Eris Lifesciences Ltd. |
| EBITDA Margin (TTM) | 26.38% | 7.95% | Eris Lifesciences Ltd. |
| Return on Equity | 10.75% | 13.45% | Jubilant Pharmova Ltd. |
| Return on Assets (TTM) | 5.00% | 6.58% | Jubilant Pharmova Ltd. |
| Free Cash Flow (TTM) | $9.10B | $-435.00M | Eris Lifesciences Ltd. |
| Dividend Yield | 0.41% | 0.85% | Jubilant Pharmova Ltd. |
| 1-Year Return | -21.75% | -10.73% | Jubilant Pharmova Ltd. |
| Price-to-Sales Ratio (TTM) | 6.31 | 1.83 | Jubilant Pharmova Ltd. |
| Enterprise Value | $217.40B | $166.18B | Eris Lifesciences Ltd. |
| EV/Revenue Ratio | 7.09 | 2.31 | Jubilant Pharmova Ltd. |
| Gross Profit Margin (TTM) | 72.12% | 66.15% | Eris Lifesciences Ltd. |
| Revenue per Share (TTM) | $225 | $500 | Jubilant Pharmova Ltd. |
| Earnings per Share (Diluted) | $31.54 | $27.21 | Eris Lifesciences Ltd. |
| Beta (Stock Volatility) | -0.14 | 0.48 | Eris Lifesciences Ltd. |
Eris Lifesciences Ltd. vs Jubilant Pharmova Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Eris Lifesciences Ltd. | -1.44% | 1.41% | 0.98% | 5.69% | -12.73% | -7.79% |
| Jubilant Pharmova Ltd. | 1.49% | 3.55% | 0.12% | 18.02% | -8.71% | -6.31% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Eris Lifesciences Ltd. | -21.75% | 112.96% | 97.43% | 133.52% | 133.52% | 133.52% |
| Jubilant Pharmova Ltd. | -10.73% | 141.98% | 33.13% | 269.98% | 702.72% | 580.28% |
Performance & Financial Health Analysis: Eris Lifesciences Ltd. vs Jubilant Pharmova Ltd.
| Metric | ERIS | JUBLPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹193.36B | ₹149.73B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 174,049 | 112,714 |
| 90 Day Avg. Volume | 106,619 | 181,191 |
| Last Close | ₹1,384.40 | ₹991.35 |
| 52 Week Range | ₹1,200.00 - ₹1,900.00 | ₹786.05 - ₹1,248.00 |
| % from 52W High | -27.14% | -20.56% |
| All-Time High | ₹1,910.00 (Jun 09, 2025) | ₹1,309.90 (Nov 04, 2024) |
| % from All-Time High | -27.52% | -24.32% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.11% | 0.17% |
| Quarterly Earnings Growth | 0.19% | -0.45% |
| Financial Health | ||
| Profit Margin (TTM) | 0.14% | 0.05% |
| Operating Margin (TTM) | 0.26% | 0.08% |
| Return on Equity (TTM) | 0.11% | 0.13% |
| Debt to Equity (MRQ) | 68.19 | 43.87 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹226.84 | ₹415.87 |
| Cash per Share (MRQ) | ₹5.49 | ₹39.24 |
| Operating Cash Flow (TTM) | ₹7.57B | ₹8.86B |
| Levered Free Cash Flow (TTM) | ₹3.52B | ₹8.39B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.41% | 0.85% |
| Last 12-Month Dividend | ₹7.35 | ₹10.00 |
Valuation & Enterprise Metrics Analysis: Eris Lifesciences Ltd. vs Jubilant Pharmova Ltd.
| Metric | ERIS (Apr 24, 2026) | JUBLPHARMA (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 44.25 | 33.71 |
| Forward P/E | 27.76 | 25.27 |
| PEG Ratio | 2.33 | -0.74 |
| Price to Sales (TTM) | 6.31 | 1.83 |
| Price to Book (MRQ) | 6.15 | 2.21 |
| Market Capitalization | ||
| Market Capitalization | ₹193.36B | ₹149.73B |
| Enterprise Value | ₹217.40B | ₹166.18B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.09 | 2.31 |
| Enterprise to EBITDA | 17.91 | 13.71 |
| Risk & Other Metrics | ||
| Beta | -0.14 | 0.48 |
| Book Value per Share (MRQ) | ₹226.84 | ₹415.87 |
Financial Statements Comparison: Eris Lifesciences Ltd. vs Jubilant Pharmova Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | ERIS (2025) | JUBLPHARMA (2025) |
|---|---|---|
| Revenue/Sales | 28.79B | 71.92B |
| Cost of Goods Sold | 7.30B | 26.12B |
| COGS % of Revenue | 25.4% | 36.3% |
| Gross Profit | 21.49B | 45.81B |
| Gross Margin | 74.6% | 63.7% |
| Research & Development | 24.40M | N/A |
| Operating Income (EBIT) | 7.03B | 8.07B |
| Operating Margin | 24.4% | 11.2% |
| EBITDA | 10.33B | 12.12B |
| EBITDA Margin | 35.9% | 16.9% |
| Pre-Tax Income | 4.89B | 9.81B |
| Pre-Tax Income % of Revenue | 17.0% | 13.6% |
| Income Tax | 1.14B | 1.44B |
| Income Tax % of Revenue | 4.0% | 2.0% |
| Net Income (Profit) | 3.75B | 8.36B |
| Profit Margin | 13.0% | 11.6% |
Balance Sheet & Liquidity Metrics
| Metric | ERIS (2025) | JUBLPHARMA (2025) |
|---|---|---|
| Cash & Equivalents | 2.00B | 10.86B |
| Total Current Assets | 12.23B | 35.77B |
| Total Current Assets % of Revenue | 42.5% | 49.7% |
| Total Current Liabilities | 13.81B | 21.65B |
| Total Current Liabilities % of Revenue | 48.0% | 30.1% |
| Long-Term Debt | 17.82B | 23.89B |
| Long-Term Debt % of Revenue | 61.9% | 33.2% |
| Total Shareholders Equity | 32.72B | 62.39B |
| Retained Earnings | 27.93B | 53.02B |
| Retained Earnings % of Revenue | 97.0% | 73.7% |
| Property, Plant & Equipment | 2.36B | 24.54B |
Cash Flow Statement Comparison
| Metric | ERIS (2025) | JUBLPHARMA (2025) |
|---|---|---|
| Operating Cash Flow | 7.57B | 8.86B |
| Operating Cash Flow % of Revenue | 26.3% | 12.3% |
| Capital Expenditures | -1.55B | -11.11B |
| Free Cash Flow | 9.10B | -435.00M |
| FCF Margin | 31.6% | -0.6% |
| Debt Repayment | -18.34B | -11.00B |
| Common Stock Repurchase | N/A | -56.00M |
Short Interest & Institutional Ownership Analysis
| Metric | ERIS | JUBLPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 138.54M | 158.39M |
| Float Shares | 43.42M | 63.53M |
| % Held by Insiders | 68.05% | 57.94% |
| % Held by Institutions | 21.83% | 20.51% |
| % Held by Public | 10.12% | 21.55% |
Dividend Analysis & Yield Comparison: Eris Lifesciences Ltd. vs Jubilant Pharmova Ltd.
| Metric | ERIS | JUBLPHARMA |
|---|---|---|
| Last 12-Month Dividend | ₹7.35 | ₹10.00 |
| Last 12-Month Dividend Yield | 0.41% | 0.85% |
| 3-Year Avg Annual Dividend | ₹4.90 | ₹6.67 |
| 3-Year Avg Dividend Yield | 0.82% | 0.89% |
| 3-Year Total Dividends | ₹14.70 | ₹20.00 |
| Ex-Dividend Date | Feb 13, 2025 | Jul 25, 2025 |